Tìm theo
Piroxicam
Các tên gọi khác (5 ) :
  • 4-Hydroxy-2-methyl-N-(2-pyridyl)-2H-1,2-benzothiazin-3-caboxyamid-1,1-dioxid
  • Feldene
  • Piroxicam
  • Piroxicamum
  • Pyroxycam
Thuốc giảm đau, hạ sốt, chống viêm không steroid, điều trị Gút và các bệnh xương khớp
Thuốc Gốc
Small Molecule
CAS: 36322-90-4
ATC: M01AC01, M02AA07, S01BC06
ĐG : Advanced Pharmaceutical Services Inc.
CTHH: C15H13N3O4S
PTK: 331.346
A cyclooxygenase inhibiting, non-steroidal anti-inflammatory agent (NSAID) that is well established in treating rheumatoid arthritis and osteoarthritis and used for musculoskeletal disorders, dysmenorrhea, and postoperative pain. Its long half-life enables it to be administered once daily. [PubChem]
Nhận Dạng Quốc Tế & Đặc Tính Hóa Học
Công thức hóa học
C15H13N3O4S
Phân tử khối
331.346
Monoisotopic mass
331.062676609
InChI
InChI=1S/C15H13N3O4S/c1-18-13(15(20)17-12-8-4-5-9-16-12)14(19)10-6-2-3-7-11(10)23(18,21)22/h2-9,19H,1H3,(H,16,17,20)
InChI Key
InChIKey=QYSPLQLAKJAUJT-UHFFFAOYSA-N
IUPAC Name
4-hydroxy-2-methyl-1,1-dioxo-N-(pyridin-2-yl)-2H-1$l^{6},2-benzothiazine-3-carboxamide
Traditional IUPAC Name
piroxicam
SMILES
CN1C(C(=O)NC2=NC=CC=C2)=C(O)C2=C(C=CC=C2)S1(=O)=O
Độ tan chảy
198-200 °C
Độ hòa tan
23 mg/L (at 22 °C)
logP
3.06
logS
-4.16
pKa (strongest acidic)
4.76
pKa (Strongest Basic)
3.79
PSA
99.6 Å2
Refractivity
87.04 m3·mol-1
Polarizability
32.27 Å3
Rotatable Bond Count
2
H Bond Acceptor Count
5
H Bond Donor Count
2
Physiological Charge
-1
Number of Rings
3
Bioavailability
1
Rule of Five
true
Ghose Filter
true
caco2 Permeability
-4.45
pKa
6.3
Dược Lực Học : Piroxicam is in a class of drugs called nonsteroidal anti-inflammatory drugs (NSAIDs). Piroxicam works by reducing hormones that cause inflammation and pain in the body. Piroxicam is used to reduce the pain, inflammation, and stiffness caused by rheumatoid arthritis and osteoarthritis.
Cơ Chế Tác Dụng : A cyclooxygenase inhibiting, non-steroidal anti-inflammatory agent (NSAID) that is well established in treating rheumatoid arthritis and osteoarthritis and used for musculoskeletal disorders, dysmenorrhea, and postoperative pain. Its long half-life enables it to be administered once daily. [PubChem] The antiinflammatory effect of Piroxicam may result from the reversible inhibition of cyclooxygenase, causing the peripheral inhibition of prostaglandin synthesis. The prostaglandins are produced by an enzyme called Cox-1. Piroxicam blocks the Cox-1 enzyme, resulting into the disruption of production of prostaglandins. Piroxicam also inhibits the migration of leukocytes into sites of inflammation and prevents the formation of thromboxane A2, an aggregating agent, by the platelets.
Dược Động Học :
▧ Absorption :
Well absorbed following oral administration.
▧ Volume of Distribution :
* 0.14 L/kg
▧ Metabolism :
Renal
▧ Route of Elimination :
Piroxicam and its biotransformation products are excreted in urine and feces, with about twice as much appearing in the urine as in the feces. Approximately 5% of a piroxicam dose is excreted unchanged. However, a substantial portion of piroxicam elimination occurs by hepatic metabolism. Piroxicam is excreted into human milk.
▧ Half Life :
30 to 86 hours
Độc Tính : Symptoms of overdose include drowsiness, nausea, stomach pain, and/or vomiting.
Chỉ Định : For treatment of osteoarthritis and rheumatoid arthritis.
Tương Tác Thuốc :
  • Acebutolol Risk of inhibition of renal prostaglandins
  • Acenocoumarol The NSAID, piroxicam, may increase the anticoagulant effect of acenocoumarol.
  • Alendronate Increased risk of gastric toxicity
  • Anisindione The NSAID, piroxicam, may increase the anticoagulant effect of anisindione.
  • Atenolol Risk of inhibition of renal prostaglandins
  • Azilsartan medoxomil Increases toxicity of each. May deteriorate renal function, particularly in volume depleted or elderly patients. Decreases effects of azilsartan by antagonism.
  • Betaxolol Nonsteroidal Anti-Inflammatory Agents such as piroxicam may diminish the antihypertensive effect of Beta-Blockers such as betaxolol. Monitor for increases in blood pressure if a nonsteroidal anti-inflammatory agent (NSAID) is initiated/dose increased, or decreases in blood pressure if a NSAID is discontinued/dose decreased; this is particularly important if NSAID treatment is for extended periods of time. Ophthalmic beta-blockers are likely of little concern.
  • Bevantolol Risk of inhibition of renal prostaglandins
  • Bisoprolol Risk of inhibition of renal prostaglandins
  • Carteolol Risk of inhibition of renal prostaglandins
  • Carvedilol Risk of inhibition of renal prostaglandins
  • Colesevelam Bile acid sequestrants may decrease the absorption of Nonsteroidal Anti-Inflammatory Agents. Monitor for decreased serum concentrations/therapeutic effects of nonsteroidal anti-inflammatory agents (NSAID) if coadministered with bile acid sequestrants. Separating the administration of doses by 2 or more hours may reduce (but not eliminate) the risk of interaction. The manufacturer of colesevelam recommends that drugs should be administered at least 1 hour before or 4 hours after colesevelam.
  • Cyclosporine Monitor for nephrotoxicity
  • Dicoumarol The NSAID, piroxicam, may increase the anticoagulant effect of dicumarol.
  • Esmolol Risk of inhibition of renal prostaglandins
  • Ginkgo biloba Additive anticoagulant/antiplatelet effects may increase bleed risk. Concomitant therapy should be avoided.
  • Labetalol Risk of inhibition of renal prostaglandins
  • Lithium The NSAID, piroxicam, may decrease the renal excretion of lithium. Increased risk of lithium toxicity.
  • Methotrexate The NSAID, piroxicam, may decrease the renal excretion of methotrexate. Increased risk of methotrexate toxicity.
  • Metoprolol Risk of inhibition of renal prostaglandins
  • Nadolol Risk of inhibition of renal prostaglandins
  • Oxprenolol Risk of inhibition of renal prostaglandins
  • Penbutolol Risk of inhibition of renal prostaglandins
  • Pindolol Risk of inhibition of renal prostaglandins
  • Practolol Risk of inhibition of renal prostaglandins
  • Pralatrexate NSAIDs increase the risk of toxicity due to impairment of renal clearance of pralatrexate thus increasing exposure. Monitor for adverse effects or adjust dose of pralatrexate.
  • Propranolol Risk of inhibition of renal prostaglandins
  • Ritonavir Ritonavir increases the toxicity of piroxicam
  • Sotalol Risk of inhibition of renal prostaglandins
  • Tamoxifen Piroxicam may reduce clearance rate of Tamoxifen. Monitor for changes in therapeutic/adverse effects of Tamoxifen if Piroxicam is initiated, discontinued or dose changed.
  • Telmisartan Concomitant use of Telmisartan and Piroxicam may increase the risk of acute renal failure and hyperkalemia. Monitor renal function at the beginning and during treatment.
  • Timolol Risk of inhibition of renal prostaglandins
  • Tolbutamide Piroxicam, a strong CYP2C9 inhibitor, may decrease the metabolism and clearance of Tolbutamide, a CYP2C9 substrate. Consider alternate therapy or monitor for changes in Tolbutamide therapeutic and adverse effects if Piroxicam is initiated, discontinued or dose changed.
  • Torasemide Piroxicam, a strong CYP2C9 inhibitor, may increase the serum concentration of Torasemide, a CYP2C9 substrate, by decreasing Torasemide metabolism and clearance. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of Torasemide if Piroxicam is initiated, discontinued or dose changed.
  • Trandolapril The NSAID, Piroxicam, may reduce the antihypertensive effect of Trandolapril. Consider alternate therapy or monitor for changes in Trandolapril efficacy if Piroxicam is initiated, discontinued or dose changed.
  • Treprostinil The prostacyclin analogue, Treprostinil, may increase the risk of bleeding when combined with the NSAID, Piroxicam. Monitor for increased bleeding during concomitant thearpy.
  • Triflusal The metabolite of triflusal, 2-hydroxy-4-trifluoro-methyl-benzoic acid (HTB), impairs the serum protein binding of glisentide to the same extent as acetylsalisylic acid. Thus, the free fraction of glisentide may be increased. A dosage reduction may be required if used in combination.
  • Trimethoprim The strong CYP2C9 inhibitor, Piroxicam, may decrease the metabolism and clearance of Trimethoprim, a CYP2C9 substrate. Consider alternate therapy or monitor for changes in therapeutic and adverse effects of Trimethoprim if Piroxicam is initiated, discontinued or dose changed.
  • Vilazodone Increased risk of bleeding with concomitant use of NSAIDs and vilazodone
  • Voriconazole Piroxicam, a strong CYP2C9 inhibitor, may increase the serum concentration of voriconazole by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of voriconazole if piroxicam is initiated, discontinued or dose changed.
  • Warfarin Piroxicam, a strong CYP2C9 inhibitor, may decrease the metabolism of warfarin. The antiplatelet effect of piroxicam may also increase the bleed risk associated with warfarin. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of warfarin if piroxicam is initiated, discontinued or dose changed.
Liều Lượng & Cách Dùng : Capsule - Oral
Suppository - Rectal
Tablet - Oral
Dữ Kiện Thương Mại
Giá thị trường
Nhà Sản Xuất
  • Công ty :
    Sản phẩm biệt dược : Bruxicam
  • Công ty :
    Sản phẩm biệt dược : Dolonex
  • Công ty :
    Sản phẩm biệt dược : Erazon
  • Công ty : Pfizer
    Sản phẩm biệt dược : Feldene
  • Công ty :
    Sản phẩm biệt dược : Geldène
  • Công ty :
    Sản phẩm biệt dược : Improntal
  • Công ty : Bosnalijek
    Sản phẩm biệt dược : Roxam
  • Công ty :
    Sản phẩm biệt dược : Roxiden
  • Công ty :
    Sản phẩm biệt dược : Sasulen
  • Công ty :
    Sản phẩm biệt dược : Solocalm
  • Công ty :
    Sản phẩm biệt dược : Trast
Đóng gói
Tài Liệu Tham Khảo Thêm
drugbank
http://www.drugbank.ca/drugs/DB00554
KEGG Compound
http://www.genome.jp/dbget-bin/www_bget?cpd:C01608
KEGG Drug
http://www.genome.jp/dbget-bin/www_bget?drug:D00127
National Drug Code Directory
http://www.hipaaspace.com/Medical_Billing/Coding/National.Drug.Codes/PDF/0378-1010-01
PharmGKB
http://www.pharmgkb.org/drug/PA450985
Wikipedia
http://en.wikipedia.org/wiki/Piroxicam
RxList
http://www.rxlist.com/cgi/generic/piroxicam.htm
PDRhealth
http://www.pdrhealth.com/drug_info/rxdrugprofiles/drugs/fel1173.shtml
Drugs.com
http://www.drugs.com/cdi/piroxicam.html
... loading
... loading